公开(公告)号：EP1306373A1

公开(公告)日：2003-05-02

申请号：EP01953336.3

申请日：2001-07-30

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： OGAWA, Mikio, Minase Res.Inst.,Ono Pharm.Co,Ltd. ,  TAKAOKA, Y., Minase Res. Inst.Ono Pharm.Co,Ltd. ,  OHHATA, Akira, Minase Res. Inst., Ono Pharm.Co,Ltd

IPC: C07D217/16 ,  C07D405/06 ,  C07D409/06 ,  C07D221/20 ,  C07D491/107 ,  C07D471/10 ,  C07D401/06 ,  C07D413/06 ,  C07D417/06 ,  C07D405/04 ,  C07D401/04 ,  C07D265/16 ,  C07D495/04 ,  C07D217/24 ,  C07D413/14

CPC classification number: C07D221/20 ,  A61K31/472 ,  A61K31/4725 ,  C07D217/16 ,  C07D217/18 ,  C07D265/14 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D491/04 ,  C07D491/10 ,  C07D495/04

Abstract: A 3,4-dihydroisoquinoline derivative compound of formula (I) or a non-toxic salt thereof and a pharmaceutical agent comprising it as active ingredient (wherein all symbols have the same meaning as described in the specification). The compound of formula (I) has agonizing activity on CB2 receptor and therefore it is useful for the prophilaxis and/or treatment of various diseases such as asthma, nasal allergy, atopic dermatitis, autoimmune diseases, rheumatoid arthritis, immune dysfunction, postoperative pain, carcinomatous pain, etc.

Abstract translation: 式（I）或无毒的盐，以及含有它作为活性成分的药物试剂的3,4-二氢异喹啉衍生物化合物（如worin在说明书中描述的所有符号具有相同的含义）。 式（I）的化合物具有对CB2受体激动活性，因此它是用于各种疾病的prophilaxis和/或治疗有用：如哮喘，鼻过敏，特应性皮炎，自身免疫性疾病，类风湿关节炎，免疫功能障碍，手术后疼痛， 癌性疼痛等

公开(公告)号：EP1306373B1

公开(公告)日：2007-05-16

申请号：EP01953336.3

申请日：2001-07-30

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： OGAWA, Mikio, Minase Res.Inst.,Ono Pharm.Co,Ltd. ,  TAKAOKA, Y., Minase Res. Inst.Ono Pharm.Co,Ltd. ,  OHHATA, Akira, Minase Res. Inst., Ono Pharm.Co,Ltd

IPC: C07D217/16 ,  C07D405/06 ,  C07D409/06 ,  C07D221/20 ,  C07D491/107 ,  C07D471/10 ,  C07D401/06 ,  C07D413/06 ,  C07D417/06 ,  C07D405/04 ,  C07D401/04 ,  C07D217/18 ,  C07D491/10 ,  C07D471/04 ,  C07D265/16 ,  C07D495/04 ,  A61K31/435 ,  A61K31/495

CPC classification number: C07D221/20 ,  A61K31/472 ,  A61K31/4725 ,  C07D217/16 ,  C07D217/18 ,  C07D265/14 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D491/04 ,  C07D491/10 ,  C07D495/04

Abstract: 3,4-Dihydroisoquinoline derivative compounds represented by the following general formula (I) (wherein each symbol has the meaning as specified in the description) or nontoxic salts thereof. Because of having a CB2 receptor agonist activity, the compounds represented by the general formula (I) are useful in preventing and/or treating various diseases, for example, asthma, nasal allergy, atopic dermatitis, autoimmune diseases, rheumatish, immnodeficiency, postoperative pain and carcinomatous pain.